

# AUTHOR GUIDELINES

These author guidelines can also be downloaded as a PDF version [here](#)

## Sections

1. [Submission and Peer Review Process](#)
2. [Article Types](#)
3. [After Acceptance](#)

## 1. Submission and Peer Review Process

Once you have checked the [Aims and Scope](#) of the *European Journal of Immunology* and the submission materials have been prepared in accordance with these Author Guidelines (please note that this journal offers [simple first \(free format\) submission](#)), manuscripts should be submitted online at <https://mc.manuscriptcentral.com/eurjimmu/>

For help with submissions, please click on “Help” in the top right hand of ScholarOne™ Manuscripts. You can also contact the editorial office: [ejied@wiley.com](mailto:ejied@wiley.com)

This journal does not charge submission fees but there are [publication fees](#).

### Article Preparation Support

[Wiley Editing Services](#) offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for [Preparing Your Article](#) for general guidance about writing and preparing your manuscript.

### Simple first (Free Format) submission

Since November 2016, the *European Journal of Immunology* has been offering simple first (Free Format) submission for an easier, streamlined submission process.

Before you submit, you will need:

- Your manuscript: this should either be a single file including text, figures, and tables, or separate files—whichever you prefer. All [required sections](#) should be contained in your manuscript but do not need to be in *European Journal of Immunology* order or format. Figures and tables should have legends and the data should be [reproducible](#). [References](#) may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be

difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.

- An [ORCID ID](https://orcid.org), freely available at <https://orcid.org>. (*Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.*)
- The [title page](#) of the manuscript including your co-author details, affiliations and email addresses (*Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.*)
- Statements relating to our [ethics and integrity policies](#) should be included before the References. These may include any of the following (*Why are these policies important? We need to uphold rigorous ethical standards for the research we consider for publication*):
  - [data availability statement](#)
  - [funding statement](#): all funding sources for the study should be included in the Acknowledgements
  - [conflict of interest](#) disclosure
  - ethics approval statement: [human and animal studies](#)
  - [patient consent](#) statement
  - [permission to reproduce material from other sources](#)
  - [clinical trial registration](#)
  - [Author contributions](#): each author's contribution to the article should be detailed
  - [Acknowledgements](#)

If you are submitting your manuscript as a single file, please select "Submission file" as the file designation.

To submit, login [here](#) and create a new submission. Follow the submission steps as required and submit the manuscript.

## Open Access

This journal is a subscription journal that offers an open access option. You'll have the option to choose to make your article open access after acceptance, which will be subject to an article publication charge (APC). You can [read more about APCs](#) and whether you may be eligible for a discount or full payment through your institution.

## Preprint policy:

Please find the Wiley preprint policy [here](#).

This journal accepts articles previously published on preprint servers. You may also post the submitted version of a manuscript to a preprint server at any time. You are requested to update any pre-publication versions with a link to the final published article.

## **Data Sharing and Data Availability**

This journal expects data sharing. Review [Wiley's Data Sharing policy](#) where you will be able to see and select the [data availability statement](#) that is right for your submission.

## **Data Citation**

Please review [Wiley's Data Citation policy](#).

## **Data Protection**

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication. Please review [Wiley's Data Protection Policy](#) to learn more.

## **Funding**

You should list [all funding sources](#) in the Acknowledgements section. You are responsible for the accuracy of their funder designation. If in doubt, please check the [Open Funder Registry](#) for the correct nomenclature.

## **Authorship**

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review [editorial standards](#) and learn about [authorship criteria](#). Mini-reviews and reviews should have a maximum of three authors unless agreed with the editorial office in advance.

## **ORCID**

This journal requires ORCID. Please refer to [Wiley's resources on ORCID](#).

## **Reproduction of Copyright Material**

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit [Wiley's Copyright Terms & Conditions FAQ](#).

The corresponding author is responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source, and for supplying Wiley with that permission upon submission.

## Title Page

The title (first) page of the main text file should only contain:

- i. A brief informative title containing the major key words. The title should not contain abbreviations (see [Wiley's best practice SEO tips](#)) and should be no more than 150 characters including spaces;
- ii. The full names (including forenames) of the authors — middle names should be indicated by initials only and surnames should be indicated by underlining;
- iii. The author's institutional affiliations where the work was conducted, with a footnote for the author's present address if different from where the work was conducted;
- iv. Name, postal address and e-mail of the corresponding author
- v. keywords (maximum of 5)
- vi. A list of abbreviations used. If an abbreviation is used three or more times in the text it should be included in the abbreviations list and defined the first time it is used in the abstract and in the main text. If it is used less than this, it should be defined in full each time it is used.

## Main Text File

The main text file should be in Word or PDF format and include:

- A [title page](#)
- Abstract (maximum 200 words) if applicable (see [article types](#))
- Main body: formatted according to article type
- References
- Tables (each table complete with title and footnotes)
- [Figures](#): Figure legends must be added as a complete list in the text. The data should be [reproducible](#), i.e. contain an appropriate number of samples, replicates, animals, patients and independent experiments (the total number of experiments performed and the number of samples, replicates, animals or donors per experiment should be clearly stated). Full statistical analysis should be provided, including the name of each statistical test used, a description of the comparisons made to obtain the p values (if not clearly indicated in the Figures), and a description of how the data are presented data e.g. SD, SEM etc. The legends should provide all this information, as well as explaining all symbols, values etc. used if a key is not provided in the Figures. Authors are encouraged to analyze data across multiple experiments and should note that analyzing replicates within a single experiment does not provide information regarding experimental reproducibility. Please also see the [best practice regarding Figures and legends](#).

For animal studies, the legend or Materials and Methods should state the age, gender, genotype and housing arrangements of the animals, detailing any co-

housing of animals of different experimental groups, particularly genetically different animals, and the length of time of such co-housing. Authors are also recommended to upload a health report of their animal facilities as Supporting Information. It should be remembered that it is not scientifically valid to compare KO mice bred amongst each other with WT mice purchased from a vendor or to breed transgenic mice without genotyping. Littermate controls will be requested as appropriate. For further information, please see this [Commentary](#).

**Please note that submitted manuscripts that do not contain complete information about the number of experiments performed, as well as the number of samples (biological or technical replicates) per experiment, will be unsubmitted, and manuscripts returned to authors for clarification.**

## Reference Style

This journal uses Vancouver reference style; as the journal offers [simple first \(free format\)](#) submission, however, this is for information only and you do not need to format the references in your article. This will instead be taken care of by the typesetter. Regardless of reference style used, please list **all** authors in the reference list. Review your [reference style guidelines](#) prior to submission. Citations in the Abstract are discouraged but, if included, should be written in parentheses in accordance with the following example (Bosco, N. et al., Eur. J. Immunol. 2008. 38: 3250-3259.) If a reference only appears in a table or figure legend, and not in the text, it should be numbered consecutively following on from the last citation in the text.

## Figures and Supporting Information

Figures, supporting information, and appendices should be supplied as separate files. You should review the [basic figure requirements](#) for manuscripts for peer review, as well as the more detailed [post-acceptance figure requirements](#). Please note the ethical considerations detailed on the last page of the figure requirements; authors must be able to produce all data in their raw format upon editorial request.

View [Wiley's FAQs](#) on supporting information. Of note, Supporting Information is not edited but is posted online as received. Please also note that Materials and methods are not allowed in the Supporting Information except for Letters to the Editor (mandatory), Technical Comments (optional) or unless the Materials and Methods pertain ONLY to data in the Supporting Information.

## Best practice examples: Figures and legends

### *Reproducibility*

To report on reproducibility: please detail all key experimental information, including the number of samples, replicates, animals/donors per experiment, the total number of experiments performed, as well as the statistical analysis and the description of how the data are presented data e.g. SD, SEM. Please see [Fig. 1](#) for an example.

### ***Flow cytometry analysis***

Please show the full gating strategy used. This should include the position of positive and negative controls and essential information, such as the percentage of cells in the region or gate or event count, and statistics as appropriate. Axis legends should include the marker (e.g. antigen) and the fluorochrome/dye used, and show a numbered scaling (log/lin). For more information how to prepare flow cytometry data analysis for publication see the EJI flow cytometry resource: [Guidelines for the use of flow cytometry and cell sorting in immunological studies](#). Adherence to the Guidelines should be noted in the Materials and Methods. Please also see [Fig. 3](#) for an example in an article.

If multiple experiments use the same gating, please show this only once. If space is limited, you may wish to include this information as Supporting Information. Please see [this example](#) of Supporting Information detailing the gating.

### ***Microscopy***

Please show scale bars and describe the length of the scale bar either in the text or in the image. Please see [Fig. 3](#) for an example.

### ***Western blots***

Please show loading controls, MW markers and clearly indicate if lanes were cropped or spliced for presentation purposes. If blots have been cropped or spliced, please provide the raw data as Supporting Information. Please see [Fig. 6](#) for an example.

Please also refer to the [Appendix](#) for detailed explanation of data sharing and assays.

### **Cover letter, ethics and permissions**

Please refer to the section [Guidelines on Publishing and Research Ethics in Journal Articles](#) and that detailing required [manuscript statements](#), as well as the information detailed here.

Manuscripts must be accompanied by a cover letter from the corresponding author. By submitting this letter, **the corresponding author accepts responsibility for all statements contained within it.**

The letter must detail in no more than 250 words the aim of the study, the novel results obtained and how the study advances our knowledge. The cover letter should not merely

repeat the Abstract of the manuscript but should clearly and accurately describe the significance of the study for those working within/outside the field. Bullet points are a recommended way of communicating this information.

Please note that EJ's [policies](#) help you avoid being scooped and **authors requesting fast track processing**, i.e. submitting either a 'Frontline: Regular Article' or a 'Frontline: Short Communication', must also **detail why** the study warrants rapid review and publication, explaining the study's superior significance for the immunological community and potentially competitive situation. Letters not including this information for "Frontline" papers will result in the manuscript being treated as a regular submission and the manuscript will not be fast-tracked.

Every cover letter must also contain clear statements covering all the following points, indicating which option applies (if more than one), detailing those that are not applicable and providing any additional information as necessary:

- 1) [All authors](#) concur with the submission.
- 2) [All funding](#) for the studies in the manuscript, together with the names of the principal funding recipients, are listed in the Acknowledgements.
- 3) All persons cited in the manuscript by way of the Acknowledgements, personal communications, unpublished observations/data concur with the citation. Any data cited in the manuscript that has been generated by persons not listed as authors, i.e. personal communications, must be accompanied by a written permission letter from the person cited. Permission letters e-mailed to [ejied@wiley.com](mailto:ejied@wiley.com) are acceptable.
- 4) The work has not been published elsewhere, either completely, in part, or in another form.
- 5) The manuscript has not been submitted to another journal and will not be published elsewhere within one year after its publication in this journal.
- 6) The manuscript does/does not contain [experiments using animals](#). The permission of the national or local (institutional review board (IRB)) authorities (giving the permission or the accreditation number of the laboratory and of the investigator) should be stated if animal experiments are included. If no such rules or permissions have been implicated in the particular country, this must be stated.
- 7) The manuscript does/does not contain [human studies](#). If such studies are included, it should be stated that local Ethical Committee (institutional review board (IRB)) approval was received for the studies and that the informed consent of all participating subjects was obtained.

**Permission statements relating to animal and human studies (points 6 and 7) must also be included in the text of the manuscript.**

- 8) Any financial/commercial [conflicts of interests](#) have been disclosed. Such conflicts should be detailed in the covering letter

**Financial/commercial conflicts of interests must also be stated in the manuscript after the Acknowledgements.**

9) Any papers by the authors that are under consideration or in press with other journals and not yet available online and are related to the manuscript submitted to the European Journal of Immunology have been submitted as supporting information.

## Peer Review

This journal operates under a single-blind, transparent [peer review model](#). Papers will only be sent to review if the Executive Committee determines that the paper meets the appropriate quality and relevance requirements.

In-house submissions, i.e. papers authored by Executive Committee or Editorial Board members of the title, will be sent to Executive Committee members unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias.

Wiley's policy on the confidentiality of the review process is [available here](#).

This journal is participating in a pilot on Peer Review Transparency and you have the choice to opt-out during the submission process. By submitting to this journal, you agree that the reviewer reports, their responses, and the editor's decision letter will be linked from the published article to where they appear on [Publons](#) in the case that the article is accepted. Reviewers can choose to remain anonymous unless they would like to sign their report.

This journal participates in Wiley's [Transfer Desk Assistant](#) program.

## Guidelines on Publishing and Research Ethics in Journal Articles

The journal requires that you [include in the manuscript](#) details IRB approvals, ethical treatment of human and animal research participants, and gathering of informed consent, as appropriate. You will be expected to declare all [conflicts of interest](#), or none, on submission. Please review Wiley's policies surrounding [human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines](#).

This journal follows the [core practices](#) of the [Committee on Publication Ethics \(COPE\)](#) and handles cases of research and publication misconduct accordingly.

This journal uses iThenticate's CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read [Wiley's Top 10 Publishing Ethics Tips for Authors](#) and [Wiley's Publication Ethics Guidelines](#).

## 2. Article Types

Please note that:

- The maximum length of the title of an article is 150 characters including spaces. See also [Wiley's best practice SEO tips](#)
- Subheadings within a Section (e.g. within Results) should be no more than 100 characters long including spaces.



Article Type	Description/Peer review	Section order	Word limit
<b>Research articles</b>	Well-characterized, novel and significant advances in immunology  Peer reviewed	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Abstract (maximum 200 words)</li> <li>• Introduction</li> <li>• Results</li> <li>• Discussion</li> <li>• Materials and methods</li> <li>• Data availability statement</li> <li>• Conflict of interest disclosure</li> <li>• Ethics approval statement for human and/or animal studies</li> <li>• Patient consent statement</li> <li>• Permission to reproduce material from other sources</li> <li>• Clinical trial registration</li> <li>• Author contributions</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Tables</li> <li>• Figure legends</li> <li>• Figures</li> <li>• Supporting Information</li> </ul>	4000 words*  50 references  5 display elements (Figures, Tables)
<b>Frontline: Research Articles</b>	As for research articles but with fast track processing due to either exceptional novelty or a significant competing paper under consideration/recently published. The editors approve/decline the frontline status.	As for research articles	As for research articles
<b>Short Communications</b>	Definitive, significant discoveries in brief	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Abstract (maximum 200 words)</li> </ul>	2700 words*  25 references

	Peer reviewed	<ul style="list-style-type: none"> <li>• Introduction</li> <li>• Results and Discussion</li> </ul> <p>This is a combined section; subheadings to indicate key findings are requested see <a href="#">this</a> as an example</p> <ul style="list-style-type: none"> <li>• Concluding Remarks</li> <li>• Data availability statement</li> <li>• Conflict of interest disclosure</li> <li>• Ethics approval statement for human and/or animal studies</li> <li>• Patient consent statement</li> <li>• Permission to reproduce material from other sources</li> <li>• Clinical trial registration</li> <li>• Author contributions</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Figure legends</li> <li>• Tables</li> <li>• Figures</li> <li>• Supporting Information</li> </ul>	3 display elements (Figures, Tables)
<b>Frontline: Short Communications</b>	As for Short Communications but with fast track processing due to either exceptional novelty or a significant competing paper under consideration/recently published. The editors approve/decline the frontline status.	As for Short Communications	As for Short Communications
<b>Reviews</b>	Thought-provoking articles that review and bring unique insights into recent and future	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Abstract (maximum 200 words)</li> <li>• Introduction</li> </ul>	Recommended 3000 words* 80 references

	<p>developments in immunology.</p> <p>Reviews are typically commissioned; however, review proposals will be considered.</p> <p>Proposals should be e-mailed to the editorial office (<a href="mailto:ejied@wiley.com">ejied@wiley.com</a>) and must detail the scope of the review and the key studies to be discussed</p> <p>Peer reviewed</p>	<ul style="list-style-type: none"> <li>• Subheadings: to indicate the key topics covered</li> <li>• Conclusions/Future Perspectives</li> <li>• Conflict of interest disclosure</li> <li>• Permission to reproduce material from other sources</li> <li>• Author contributions</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Figure legends</li> <li>• Tables</li> <li>• Figures</li> </ul>	<p>4 display elements (Figures, Tables)</p>
<b>Mini-reviews</b>	As per reviews	As for reviews	<p>Recommended</p> <p>2000 words*</p> <p>50 references</p> <p>2 display elements (Figures, Tables)</p>
<b>Commentaries</b>	<p>Typically commissioned articles commenting on research published in the journal. Unsolicited opinion articles are not considered for publication.</p> <p>Not typically peer-reviewed; handled on a case-by-case basis</p>	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Abstract (maximum 200 words)</li> <li>• Subheadings: to indicate the key topics covered</li> <li>• Conflict of interest disclosure</li> <li>• Permission to reproduce material from other sources</li> <li>• Author contributions</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Figure legends</li> <li>• Tables</li> <li>• Figures</li> </ul>	<p>2000 words*</p> <p>30 references</p> <p>1 display element (Figure, Table)</p>
<b>Letters to the Editor</b>	Detail in a very short format thought-provoking, significant,	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Single text section written to the Editor as per Correspondence</li> </ul>	<p>Strict limit of 1400 words*</p>

	<p>preliminary studies, including but not limited to case studies, observational studies and confirmatory reports. Letters are indexed in Pubmed and citable</p> <p>Peer-reviewed</p>	<ul style="list-style-type: none"> <li>• Data availability statement</li> <li>• Conflict of interest disclosure</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Figure legends</li> <li>• Tables</li> <li>• Figures</li> </ul> <p>Detailed methodology, which may contain additional figures and references, should be provided as Supporting Information. The Supporting Information should also detail the following:</p> <ul style="list-style-type: none"> <li>• Ethics approval statement for human and/or animal studies</li> <li>• Patient consent statement</li> <li>• Clinical trial registration</li> <li>• Author contributions</li> <li>• Permission to reproduce material from other sources</li> </ul> <p>Please note that there is no Abstract</p>	<p>Strict limit of 10 references</p> <p>2 display elements (Figures, Tables)</p>
<p><b>Correspondence</b></p>	<p>Brief feedback on articles published in the journal or more general matters of pertinent interest to the readers; a reply may be published if applicable</p> <p>Not typically peer-reviewed; handled on a case-by-case basis</p>	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Single text section written to the Editor</li> <li>• Data availability statement</li> <li>• Conflict of interest disclosure</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Figure legends</li> <li>• Tables</li> <li>• Figures</li> </ul> <p>If appropriate, detailed methodology, which may contain additional figures and references, should be provided as Supporting</p>	<p>Strict limit of 1000 words*</p> <p>Strict limit of 10 references</p> <p>2 display elements (Figures, Tables)</p>

		<p>Information. The Supporting Information should also detail the following:</p> <ul style="list-style-type: none"> <li>• Ethics approval statement for human and/or animal studies</li> <li>• Patient consent statement</li> <li>• Clinical trial registration</li> <li>• Author contributions</li> <li>• Permission to reproduce material from other sources</li> </ul> <p>If there is no Supporting information, all relevant statements should be included in the main text before the Acknowledgements.</p> <p>Please note that there is no Abstract</p>	
<p><b>Technical Comments</b></p>	<p>Concise comments on methods noting e.g. technical advances, pitfalls etc. that are of significant importance for the immunological community.</p> <p>Peer-reviewed</p>	<ul style="list-style-type: none"> <li>• Title page</li> <li>• Single text section written to the Editor as per Correspondence.</li> <li>• Data availability statement</li> <li>• Conflict of interest disclosure</li> <li>• Acknowledgements, including funding</li> <li>• References</li> <li>• Figure legends</li> <li>• Tables</li> <li>• Figures</li> </ul> <p>Detailed methodology, which may contain additional figures and references, should be provided as Supporting Information. The Supporting Information should also detail the following:</p> <ul style="list-style-type: none"> <li>• Ethics approval statement for human and/or animal studies</li> <li>• Patient consent statement</li> <li>• Clinical trial registration</li> <li>• Author contributions</li> </ul>	<p>Strict limit of 1500 words*</p> <p>Strict limit of 15 references</p> <p>2 display elements (Figures, Tables)</p>

		<ul style="list-style-type: none"> <li>• Permission to reproduce material from other sources</li> </ul> <p>Please note that there is no Abstract</p>	
<b>Meeting reports</b>	No longer considered		
<b>Viewpoints</b>	No longer considered		

\*Word limits include the full text of the manuscript ([Title page](#), Abstract, Section headings, subheadings, [statements relating to ethics and integrity policies](#), Figure legends and Tables) but exclude references and, if present, Supporting Information. Please note that there is a [publication fee](#), which is linked to the length of a typeset article; Correspondence and commissioned articles are exempt from the fee. The recommended limits typically correspond to a 7-page research article and a 5-page short communication but this cannot be guaranteed as Figure/Table size greatly influences the final number of typeset pages.

### 3. After Acceptance

#### First Look

After your paper is accepted, your files will be assessed by the editorial office to ensure they are ready for production. You may be contacted if any updates or final files are required. Otherwise, your paper will be sent to the production team.

#### Wiley Author Services

When an accepted article is received by Wiley's production team, the corresponding author will receive an email asking them to login or register with [Wiley Author Services](#). You will be asked to sign a publication license at this point as well as arrange payment of the [open access](#) fee if applicable.

#### Copyright & Licensing

You may choose to publish under the terms of the journal's standard copyright agreement, or [Open Access](#) under the terms of a Creative Commons License.

Standard [re-use and licensing rights](#) vary by journal. Note that [certain funders](#) mandate a particular type of CC license be used. This journal uses the CC-BY/CC-BY-NC/CC-BY-NC-ND [Creative Commons License](#).

*Self-Archiving Definitions and Policies:* Note that the journal's standard copyright agreement allows for [self-archiving](#) of different versions of the article under specific conditions.

## **Accepted Articles**

The journal offers Wiley's Accepted Articles service for all primary research manuscripts. Manuscripts accepted 'in press' are published online shortly after acceptance, prior to copy-editing or typesetting and appear in PDF format only. After the final version article is published (the article of record), the DOI remains valid and can still be used to cite and access the article.

Accepted Articles will be indexed by PubMed; submitting authors should carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is accurate for indexing. The final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will update automatically.

## **Proofs**

Authors will receive an e-mail notification with their proofs included as a pdf. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email.

## **Article Promotion Support**

[Wiley Editing Services](#) offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

## **Author Name Change Policy**

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author's privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal's Editorial Office with their name change request.

## **Correction to authorship**

In accordance with Wiley's [Best Practice Guidelines on Research Integrity and Publishing Ethics](#) and the [Committee on Publication Ethics'](#) guidance, the European Journal of

Immunology will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the [Request for Changes to a Journal Article Author List Form](#) and contact either the journal's editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author's name; the relevant policy for that can be found in [Wiley's Best Practice Guidelines](#) under "Author name changes after publication."]

## Appendix

### Graphical TOC

The journal's table of contents will be presented in graphical form with a brief abstract.

The table of contents entry consists of 2-3 sentences of text (no more than 80 words) summarizing the key findings presented in the paper and a figure that conveys the main message of your article in a simple and colourful manner.

The image supplied should fit within the dimensions of 50mm x 60mm and be fully legible at this size.

### Publication Fees

There are no charges for color figures.

For authors who wish to choose the [open access](#) option, the article publication charge is Euro 3300/USD 3850/GBP 2750 (plus tax where applicable).

For authors who do not choose the [open access](#) option, the article publication charges (plus tax where applicable) are as follows:

- Euro 500 for Technical Comments/Letters to the Editor
- Euro 1000 for Short Communications longer than 5 typeset pages
- Euro 1600 for Research Articles longer than 7 typeset pages

To calculate the approximate number of pages your typeset article will have, count the number of text pages, tables and figures and divide the total by three. If your article is shorter than the indicated number of pages for Short Communications/Research Articles and is not open access, there is no fee. An invoice will be sent approx. three weeks after publication of the issue.

If you have any further inquiries, please contact our Production Department at: [ariesenk@wiley.com](mailto:ariesenk@wiley.com)



## Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

## Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see [varnomen.hgvs.org](http://varnomen.hgvs.org), where examples of acceptable nomenclature are provided.

## T-cell assays (MIATA)

Authors are encouraged to provide information on T-cell assays according to MIATA (Minimal Information About T-cell Assays) guidelines. MIATA is a reporting framework intended to provide transparency of experimental conditions and to facilitate data reproducibility by independent research groups. Authors who have documented their T-cell assays according to MIATA guidelines are requested to include this information in the Materials and methods section (e.g. The T-cell assays were carried out as follows: (description according to MIATA guidelines); the authors declare that the T-cell assays have been described according to MIATA guidelines. Once the paper has been accepted following peer-review, authors will be requested to confirm their compliance (i.e. self- declaration) by email to [contact@miataproject.org](mailto:contact@miataproject.org) and include the complete reference and an image of the front page of your paper, if it is not open access. For more information on MIATA, see the MIATA website at <http://miataproject.org/>

## MIFlowCyt

Flow cytometry experiments should be [MIFlowCyt](http://miflowcyt.org) (Minimum Information about a flow cytometry experiment) compliant. Essential details of flow experiments should be displayed in order to allow others to accurately reproduce the experiments.

See also <http://flowcyt.sourceforge.net/> or <https://fairsharing.org/collection/MIBBI> for further information.

## Microarray data

Microarray experiments should be MIAME compliant, please see <http://fged.org/projects/miame/> for more information. In addition, authors are encouraged to submit the complete microarray data relating to that published in the manuscript to an appropriate public database such as:

- **GEO:** [www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)
- **Array Express:** [www.ebi.ac.uk/arrayexpress/](http://www.ebi.ac.uk/arrayexpress/) (scheduled to be replaced by <https://www.ebi.ac.uk/biostudies/>)
- **GEA:** <https://www.ddbj.nig.ac.jp/gea/submit-array-e.html>

## Sequence Data

**Nucleotide sequence data** can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: 'These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345'. Addresses are as follows:

- DNA Data Bank of Japan (DDBJ): [www.ddbj.nig.ac.jp](http://www.ddbj.nig.ac.jp)
- EMBL Nucleotide Archive: [www.ebi.ac.uk/ena](http://www.ebi.ac.uk/ena)
- GenBank: [www.ncbi.nlm.nih.gov/genbank](http://www.ncbi.nlm.nih.gov/genbank)

**Protein sequence data** should be submitted to either of the following repositories:

- Protein Information Resource (PIR): <http://pir.georgetown.edu>
- SWISS-PROT: [www.expasy.ch/sprot/sprot-top.html](http://www.expasy.ch/sprot/sprot-top.html)

## Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). **Please note that the data in databanks must be released, at the latest, upon publication of the article.** We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

- **Organic and organometallic compounds:** Crystallographic data should not be sent as Supporting Information, but should be deposited with the *Cambridge Crystallographic Data Centre* (CCDC) at [www.ccdc.cam.ac.uk/services/structure\\_deposit](http://www.ccdc.cam.ac.uk/services/structure_deposit).
- **Inorganic compounds:** *Fachinformationszentrum Karlsruhe* (FIZ; <https://icsd.products.fiz-karlsruhe.de/en/crystalstructure/crystal-structure-depot>).
- **Proteins and nucleic acids:** *Protein Data Bank* ([www.rcsb.org/pdb](http://www.rcsb.org/pdb)).
- **NMR spectroscopy data:** *BioMagResBank* ([www.bmrb.wisc.edu](http://www.bmrb.wisc.edu)).

## Cover Image Submissions

This journal accepts artwork submissions for Cover Images. This is an optional service you can use to help increase article exposure and showcase your research. For more information, contact the editorial office [ejied@wiley.com](mailto:ejied@wiley.com)

[Wiley Editing Services](#) offers a professional cover image design service that creates eye-catching images, ready to be showcased on the journal cover.

### **Additional Guidelines for Cover Pictures and Table of Contents Graphics**

- Concepts illustrated in graphical material must clearly fit with the research discussed in the accompanying text.
- Images featuring depictions or representations of people must not contain any form of objectification, sexualization, stereotyping, or discrimination. We also ask authors to consider community diversity in images containing multiple depictions or representations of people.
- Inappropriate use, representation, or depiction of religious figures or imagery, and iconography should be avoided.
- Use of elements of mythology, legends, and folklore might be acceptable and will be decided on a case-by-case basis. However, these images must comply with the guidelines on human participants when they are present.
- Generally, authors should consider any sensitivities when using images of objects that might have cultural significance or may be inappropriate in the context (for example, religious texts, historical events, and depictions of people).
- Legal requirements:
- All necessary copyright permission for the reproduction of the graphical elements used in visuals must be obtained prior to publication.
- Clearance must be obtained from identifiable people before using their image on the cover or the like and such clearance must specify that it will be used on the cover. Use within text does not require such clearance unless it discloses sensitive personal information such as medical information. In all situations involving disclosure of such personal info, specific permission must be obtained. And images of individuals should not be used in a false manner.

*Graphics that do not adhere to these guidelines will be recommended for revision or will not be accepted for publication.*

### **Transfer policies**

Manuscripts that are not recommended for publication in the *European Journal of Immunology* due to a low priority rating, but that are well written and contain solid research, may be potential candidates for publication in [Immunity, Inflammation and Disease](#), a peer-reviewed, open access, interdisciplinary journal providing rapid publication of high-quality research in immunology.

### **Sharing of materials**

All materials and reagents that are not commercially available (antibodies, cell lines, constructs etc.) and associated protocols detailed in manuscripts published in the *European Journal of Immunology* are to be freely available to academic researchers in a timely manner

upon request. The authors agree to this condition by submitting a manuscript to the *European Journal of Immunology*.